Lyra Therapeutics CEO Palasis sells $13944 in stock

Published 15/07/2025, 02:36
Lyra Therapeutics CEO Palasis sells $13944 in stock

Maria Palasis, President and CEO of Lyra Therapeutics, Inc. (NASDAQ:LYRA), sold 1565 shares of common stock on July 10, 2025, at a price of $8.91, for a total of $13944. The transaction occurred as the stock trades near $8.71, down roughly 43% over the past year. According to InvestingPro analysis, the company currently appears undervalued relative to its Fair Value.

Following the transaction, Palasis directly owns 1098435 shares of Lyra Therapeutics.

The sale was executed to cover taxes upon the vesting of restricted stock units, according to a pre-arranged Rule 10b5-1 trading plan adopted on January 1, 2025.

In other recent news, Lyra Therapeutics has reported significant developments that may interest investors. The company announced positive results from its Phase 3 ENLIGHTEN-2 trial for LYR-210, a treatment for chronic rhinosinusitis, which met its primary and key secondary endpoints. This achievement contrasts with the earlier ENLIGHTEN-1 trial, which did not succeed. Following these results, H.C. Wainwright raised its price target for Lyra Therapeutics to $16, maintaining a Neutral rating. Meanwhile, Lyra has regained compliance with Nasdaq’s minimum bid price requirement, as confirmed by a recent SEC filing. The company also secured approximately $5 million through a registered direct offering of common stock and warrants. Lyra intends to use these funds for working capital and other corporate purposes, including the development and potential commercialization of LYR-210. The company is planning to engage with the FDA to discuss a New Drug Application for patients without nasal polyps. As these developments unfold, investors are keenly observing the company’s strategic moves and regulatory interactions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.